Communiqués Immunovant, Inc.

Actions

IMVT

US45258J1025

Temps réel estimé Cboe BZX Autres places de cotation 16:34:22 16/07/2024			Varia. 5j.	Varia. 1 janv.
30,84 ^USD	+1,07 %		+4,33 %	-26,45 %

03/06	IMMUNOVANT, INC. : Oppenheimer toujours à l'achat	ZM
30/05	Mise à jour sectorielle : Les actions du secteur de la santé mitigées avant la cloche jeudi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024	29/05	AQ
Immunovant Awarded U.S. Patent for IMVT-1402	12/03	AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023	12/02	AQ
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	20/12	AQ
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	28/11	AQ
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	28/11	AQ
Immunovant to Present at Upcoming Investor Conferences	13/11	AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023	09/11	AQ
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares	02/10/23	AQ
Immunovant Announces Pricing of $450 Million Common Stock Financing	28/09/23	AQ
Immunovant Announces Proposed Offering of $300 Million of Common Stock	26/09/23	AQ
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	26/09/23	AQ
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023	26/09/23	AQ
Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	20/09/23	PR
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023	10/08/23	AQ
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023	22/05/23	AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01/05/23	AQ
IMMUNOVANT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	27/03/23	AQ
IMMUNOVANT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	03/02/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Immunovant, Inc.

Actions

IMVT

US45258J1025

Communiqués

Filtres